When Jurassic Park came out, everyone wanted a pet dinosaur. Strictly Reptiles in Hollywood, Florida was suddenly selling 5,000 green iguanas a week. Those iguanas grew up, got released, and are now falling out of trees across South Florida — a textbook case of pop culture triggering ecological disaster.
Where this was said
At 22:10 · chapter starts 20:19
Joe Rogan pulls up YouTube videos of Florida hunters harvesting enormous male iguanas — orange-tinged, 4.5 to 5 feet long, marinated and grilled — while Eric explains that Florida is home to at least a dozen invasive reptile species, all originally pets. He corrects Rogan's assumption that common green iguanas are the only iguana worth knowing about, running through 45 species from the pink Galápagos iguana to the once-thought-extinct Jamaican iguana. [1] — Eric Goode "45 iguana species worldwide: There are approximately 45 species of iguanas in the world, many of them rare and endangered, not just the inv…" 24:29 Then Jeremy McBride sets the table for the docuseries' central story: Ray and Mike Van Nostrand of Strictly Reptiles built what was effectively an Amazon fulfillment center for exotic wildlife in Hollywood, Florida — selling 5,000 green iguanas a week at the peak of the Jurassic Park craze — a business that would evolve into a multimillion-dollar operation and eventually become a flashpoint for law enforcement, drug traffickers, and wildlife smugglers.
After Jurassic Park's release, the reptile supplier Strictly Reptiles in Hollywood, Florida was selling 5,000 green iguanas a week, driven by the pet dinosaur craze.
There are approximately 45 species of iguanas in the world, many of them rare and endangered, not just the invasive green iguanas found in Florida.
The widely shared claim that we have a credit card's worth of plastic in our brains may be a massive overestimate. Researchers used nitrile gloves to measure microplastics — and nitrile gloves shed microplastic particles onto the measuring device. A second paper found the original tool used was unreliable, and that we may have far less plastic than reported.
RSD isn't just hurt feelings — it's a dopamine-deficient brain with a hyperactive amygdala and a frayed connection to the prefrontal cortex. Add a surge of norepinephrine and you get chest pain, sweating, and trembling that convinces your body something catastrophic is happening.
In Dan Ariely's door experiment, participants sacrificed the highest-reward door — repeatedly — just to avoid seeing other doors disappear. Even when researchers trained them to use the best door, they kept wasting clicks to maintain options. This is the bias that runs our lives: we'll take a worse outcome to preserve the feeling of optionality.
Dan Gilbert discovered that the brain has a 'psychological immune system' — it misremembers, reframes, and rationalizes to keep you satisfied with whatever you chose. The fear before commitment is all about potential regret. But after committing, your brain quietly starts justifying the choice — and the more irreversible the decision, the stronger the effect.
The psychological immune system can get you through the first few months of any commitment. But durable, long-term well-being requires self-concordance — choosing commitments that are genuinely aligned with your values and what you actually want. Without that alignment, the satisfaction fades fast.
Vision didn't just help animals find food — it ignited the Cambrian explosion of speciation. Half of the human cortex is devoted to visual processing, and that same visual hierarchy directly inspired the neural network architectures powering today's AI.
Peptides come loaded with a powerful narrative: regenerative, subcutaneous, targeted, cutting-edge. That narrative can genuinely move outcomes, especially for pain, energy, and recovery. The RCT's job is to quantify how much additional benefit comes from the molecule itself — above and beyond the compelling story surrounding it.
A pharmaceutical is not an amino acid sequence — it is the successful solution to manufacturing, purification, formulation, and consistency challenges. When clinical trials prove a drug works, they validate a specific product under specific processes, not every preparation that shares the same sequence.
Ask one question of any peptide advocate: what evidence would prove this claim wrong? If every disappointing result gets attributed to wrong dose, bad supplier, wrong timing, or improper stacking, the hypothesis is not falsifiable — and a non-falsifiable claim is not a scientific claim.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.